Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Empaguard
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Empaguard is an oral small molecule drug developed and marketed by JW Pharmaceutical (a subsidiary of JW Holdings) in South Korea. It contains empagliflozin, a selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2). By inhibiting SGLT2 in the proximal renal tubules, the drug reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby promoting urinary glucose excretion. This mechanism effectively lowers blood glucose levels in patients with type 2 diabetes. Beyond glycemic control, SGLT2 inhibitors like Empaguard provide significant cardiorenal benefits, including a reduced risk of hospitalization for heart failure and slowing the progression of chronic kidney disease, likely through mechanisms involving osmotic diuresis and reduction in intraglomerular pressure.
- Brand names
- Empaguard
- Other names
- empagliflozin엠파가드
02
Targets
GLUT1 (Glucose transporter 1)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)SCN5A (Sodium channel protein type 5 subunit alpha)SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on Empaguard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empaguard.